Cargando…
The Parkinson’s disease death rate: carbidopa and vitamin B6
The only indication for carbidopa and benserazide is the management of L-3,4-dihydroxyphenylalanine (L-dopa)-induced nausea. Both drugs irreversibly bind to and permanently deactivate pyridoxal 5′-phosphate (PLP), the active form of vitamin B6, and PLP-dependent enzymes. PLP is required for the func...
Autores principales: | Hinz, Marty, Stein, Alvin, Cole, Ted |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211847/ https://www.ncbi.nlm.nih.gov/pubmed/25364278 http://dx.doi.org/10.2147/CPAA.S70707 |
Ejemplares similares
-
Parkinson’s disease: carbidopa, nausea, and dyskinesia
por: Hinz, Marty, et al.
Publicado: (2014) -
Parkinson’s disease-associated melanin steal
por: Hinz, Marty, et al.
Publicado: (2014) -
The Parkinson’s Disease Death Rate: Carbidopa and Vitamin B6 [Retraction]
Publicado: (2021) -
The Parkinson’s Disease Death Rate: Carbidopa and Vitamin B6 [Expression of Concern]
Publicado: (2020) -
Parkinson’s disease managing reversible neurodegeneration
por: Hinz, Marty, et al.
Publicado: (2016)